Business Wire

Aramco Unveils Recycled Basketball Courts, Boosting "Shoot for the Future" Project

29.11.2024 02:45:00 CET | Business Wire | Press release

Share

Aramco, one of the world’s leading integrated energy and chemicals companies, has unveiled the first three renovated community basketball courts on Tuesday in Dongdan basketball community, Beijing, China.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241128606707/en/

Aramco has unveiled the first three renovated community basketball courts on Tuesday in Beijing, China. (Photo: Business Wire)

These courts, which were built with innovative and advanced materials, with the flooring made partly from recycled plastic, are part of Aramco’s “Shoot for the Future” basketball court revamp project, with the goal of injecting new energy into community basketball in China.

The project also aims to showcase the increasingly important role that advanced materials can play in a circular carbon economy, while helping with Aramco’s objective to support and empower communities and youth through sports, and to bring green development and recycling technology to a new height as well.

Nader Al-Arfaj, Managing Director in China of Aramco Asia, said that these courts not only tell an inspiring story about how Aramco aims to empower communities and individuals through sports, but also showcase Aramco's leadership in innovation, highlighting how we can use advanced materials to shape a better future.

“I think the significance of our cooperation is quite profound,” Jian Jiang, General Manager of CBA Company, the Chinese Basketball League operation unit, said. “The project carries many meanings behind it, such as its high-tech content, innovation, social responsibility, circular economy, and many other modern concepts. In fact, this project has inspired fans a lot.”

Xiaochuan Zhai, a top Chinese basketball player, said the floor has more mesh like holes, “So, water drains away quickly after rain, which makes it better than the previous kind of floors.”

Hansen Yang, a talented young Chinese player said, “The court's color is very bright, and its rebound and anti-slip effects are quite good, so it's more comfortable to play on it.”

To bring this project to life, Aramco has worked closely with its chemical arm SABIC, and Enlio, the exclusive supplier for 3X3 basketball floors for the Tokyo and Paris Olympics. “Central to these courts is a professional-standard flooring which uses recycled materials,” Al-Arfaj added.

Aramco stressed it will continue working with partners to achieve the ambition of building courts across the country.

Al-Arfaj said, “I think we will all find these courts exceptionally impressive, and we look forward to seeing the community enjoy these courts for years to come.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20241128606707/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release

The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u

Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release

Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye